Literature DB >> 32125485

Ketamine relieves depression-like behaviors induced by chronic postsurgical pain in rats through anti-inflammatory, anti-oxidant effects and regulating BDNF expression.

Yitian Yang1, Yuxiang Song2, Xuan Zhang3, Weixing Zhao2, Tao Ma4, Yi Liu2, Penglei Ma5, Yifan Zhao6, Hong Zhang7.   

Abstract

RATIONALE: Clinically, chronic postsurgical pain (CPSP) is very common. Many CPSP patients may experience depression. Thus far, little is known about the mechanism of the comorbidity of CPSP and depression. Ketamine has been confirmed to possess analgesic and rapid antidepressant effects, but it is unclear whether ketamine can relieve the comorbidity of CPSP and depression.
OBJECTIVES: The present study evaluated the effects of ketamine in rats with the comorbidity of CPSP and depression.
METHODS: We induced CPSP in rats by thoracotomy and screened for rats with or without depression-like phenotype by hierarchical cluster analysis based on the results of depression-related behavioral experiments. Subsequently, rats were intraperitoneally injected with ketamine (20 mg/kg) and were evaluated by mechanical withdrawal threshold, cold hyperalgesia test, sucrose preference test, forced swimming test, and open field test. The inflammatory-related cytokines (IL-1, IL-6, TNF-α, nuclear factor-kappaB), oxidative stress parameters (superoxide dismutase, malondialdehyde, glutathione, catalase), and brain-derived neurotrophic factor (BDNF) in rat hippocampus were detected.
RESULTS: In the hippocampus of rats with the comorbidity of CPSP and depression, IL-1, IL-6, TNF-α, nuclear factor-kappaB, and malondialdehyde were significantly increased, while superoxide dismutase, glutathione, catalase, and BDNF were significantly decreased. Ketamine relieved depression but did not attenuate hyperalgesia in CPSP rats. Additionally, ketamine reduced proinflammatory cytokines, inhibited oxidative stress, and elevated BDNF levels in rat hippocampus.
CONCLUSIONS: Ketamine can rapidly relieve CPSP-induced depression in rats, which may be related to the reduction of proinflammatory cytokines, regulating oxidative stress and increasing BDNF in the hippocampus.

Entities:  

Keywords:  Brain-derived neurotrophic factor; Chronic postsurgical pain; Depression; Hippocampus; Ketamine; Neuroinflammation; Oxidative stress

Mesh:

Substances:

Year:  2020        PMID: 32125485     DOI: 10.1007/s00213-020-05490-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  54 in total

1.  Preliminary validation of natural depression in macaques with acute treatments of the fast-acting antidepressant ketamine.

Authors:  Xunxun Chu
Journal:  Behav Brain Res       Date:  2018-11-30       Impact factor: 3.332

Review 2.  The use of ketamine as an antidepressant: a systematic review and meta-analysis.

Authors:  Caoimhe M Coyle; Keith R Laws
Journal:  Hum Psychopharmacol       Date:  2015-04-07       Impact factor: 1.672

Review 3.  In Vogue: Ketamine for Neuroprotection in Acute Neurologic Injury.

Authors:  Josh D Bell
Journal:  Anesth Analg       Date:  2017-04       Impact factor: 5.108

4.  Neuropathic pain-induced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFR1 signaling.

Authors:  Anna Dellarole; Paul Morton; Roberta Brambilla; Winston Walters; Spencer Summers; Danielle Bernardes; Mariagrazia Grilli; John R Bethea
Journal:  Brain Behav Immun       Date:  2014-06-02       Impact factor: 7.217

5.  Effect of co-administration of memantine and sertraline on the antidepressant-like activity and brain-derived neurotrophic factor (BDNF) levels in the rat brain.

Authors:  Meysam Amidfar; Gislaine Z Réus; João Quevedo; Yong-Ku Kim; Mohammad Arbabi
Journal:  Brain Res Bull       Date:  2016-11-05       Impact factor: 4.077

Review 6.  Neuroinflammatory Mechanisms Linking Pain and Depression.

Authors:  Nikita N Burke; David P Finn; Michelle Roche
Journal:  Mod Trends Pharmacopsychiatry       Date:  2015-09-18

Review 7.  The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior.

Authors:  Kathryn G Commons; Aram B Cholanians; Jessica A Babb; Daniel G Ehlinger
Journal:  ACS Chem Neurosci       Date:  2017-03-22       Impact factor: 4.418

8.  Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness.

Authors:  Yi Che; Jun-Feng Wang; Li Shao; Trevor Young
Journal:  J Psychiatry Neurosci       Date:  2010-09       Impact factor: 6.186

9.  Characterization of a new animal model for evaluation of persistent postthoracotomy pain.

Authors:  Asokumar Buvanendran; Jeffrey S Kroin; James M Kerns; Subhash N K Nagalla; Kenneth J Tuman
Journal:  Anesth Analg       Date:  2004-11       Impact factor: 5.108

10.  Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.

Authors:  Anthony Cleare; C M Pariante; A H Young; I M Anderson; D Christmas; P J Cowen; C Dickens; I N Ferrier; J Geddes; S Gilbody; P M Haddad; C Katona; G Lewis; A Malizia; R H McAllister-Williams; P Ramchandani; J Scott; D Taylor; R Uher
Journal:  J Psychopharmacol       Date:  2015-05-12       Impact factor: 4.153

View more
  10 in total

1.  Predictors of Chronic Postsurgical Pain in Elderly Patients Undergoing Hip Arthroplasty: A Multi-Center Retrospective Cohort Study.

Authors:  Yi Lu; Bang Hu; Haitao Dai; Bao Wang; Jiayin Yao; Xinhua Yao
Journal:  Int J Gen Med       Date:  2021-11-10

Review 2.  Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders.

Authors:  Miguel Pérez de la Mora; Dasiel O Borroto-Escuela; Minerva Crespo-Ramírez; José Del Carmen Rejón-Orantes; Daniel Alejandro Palacios-Lagunas; Magda K Martínez-Mata; Daniela Sánchez-Luna; Emiliano Tesoro-Cruz; Kjell Fuxe
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

3.  Ketamine administration ameliorates anesthesia and surgery-induced cognitive dysfunction via activation of TRPV4 channel opening.

Authors:  Qi Li; Dong-Na Zhou; Yi-Qing Tu; Xin-Wei Wu; Da-Qing Pei; Yun Xiong
Journal:  Exp Ther Med       Date:  2022-06-01       Impact factor: 2.751

4.  Dexmedetomidine and Ketamine Attenuated Neuropathic Pain Related Behaviors via STING Pathway to Induce ER-Phagy.

Authors:  Yongda Liu; Shihui Kuai; Mengmeng Ding; Zhibin Wang; Limei Zhao; Ping Zhao
Journal:  Front Synaptic Neurosci       Date:  2022-05-13

Review 5.  The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.

Authors:  Esmé Jansen van Vuren; Stephan F Steyn; Christiaan B Brink; Marisa Möller; Francois P Viljoen; Brian H Harvey
Journal:  Biomed Pharmacother       Date:  2021-01-01       Impact factor: 6.529

Review 6.  The neurobiology of pain and facial movements in rodents: Clinical applications and current research.

Authors:  Adriana Domínguez-Oliva; Daniel Mota-Rojas; Ismael Hernández-Avalos; Patricia Mora-Medina; Adriana Olmos-Hernández; Antonio Verduzco-Mendoza; Alejandro Casas-Alvarado; Alexandra L Whittaker
Journal:  Front Vet Sci       Date:  2022-09-29

Review 7.  Th17 Cells in Depression: Are They Crucial for the Antidepressant Effect of Ketamine?

Authors:  Meiying Cui; Wanlin Dai; Jing Kong; Hongzhi Chen
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 8.  Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?

Authors:  Grace A Porter; Jason C O'Connor
Journal:  World J Psychiatry       Date:  2022-01-19

Review 9.  Antioxidant Biomolecules and Their Potential for the Treatment of Difficult-to-Treat Depression and Conventional Treatment-Resistant Depression.

Authors:  María Eugenia Riveros; Alba Ávila; Koen Schruers; Fernando Ezquer
Journal:  Antioxidants (Basel)       Date:  2022-03-11

10.  Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review.

Authors:  Emma Kopra; Valeria Mondelli; Carmine Pariante; Naghmeh Nikkheslat
Journal:  J Psychopharmacol       Date:  2021-06-26       Impact factor: 4.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.